Evidence map›Paper›PMID 36080138›Full record

ArticleMolecules (Basel, Switzerland)2022

Chitosan/Gamma-Alumina/Fe

Narges Ajalli, Mehrab Pourmadadi, Fatemeh Yazdian, Hamid Rashedi, Mona Navaei-Nigjeh, Ana M Díez-Pascual

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Biopolymer Composites 2022.International journal of molecular sciences · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Narges AjalliDepartment of Chemical Engineering, Faculty of Engineering, University of Tehran, Tehran 1417935840, Iran.
Mehrab PourmadadiDepartment of Chemical Engineering, Faculty of Engineering, University of Tehran, Tehran 1417935840, Iran.
Fatemeh YazdianDepartment of Life Science Engineering, Faculty of New Science and Technologies, University of Tehran, Tehran 1439956191, Iran.
Hamid RashediDepartment of Chemical Engineering, Faculty of Engineering, University of Tehran, Tehran 1417935840, Iran.ORCID 0000-0002-8460-0841
Mona Navaei-NigjehPharmaceutical Sciences Research Center, Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Ana M Díez-PascualUniversidad de Alcalá, Facultad de Ciencias, Departamento de Química Analítica, Química Física e Ingeniería Química, Ctra. Madrid-Barcelona, Km. 33.6, 28805 Alcalá de Henares, Madrid, Spain.ORCID 0000-0001-7405-2354
University of Tehran · IRTehran University of Medical Sciences · IRUniversidad de Alcalá · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, cancer treatment is an important issue in the medical world due to the challenges and side effects of ongoing treatment procedures. Current methods can be replaced with targeted nano-drug delivery systems to overcome such side effects. In the present work, an intelligent nano-system consisting of Chitosan (Ch)/Gamma alumina (γAl)/Fe

Indexed as

ChitosanNanoparticlesNeoplasmsAluminum OxideDrug CarriersFluorouracilHumansSpectroscopy, Fourier Transform InfraredX-Ray DiffractionAluminum OxideChitosanDrug CarriersFluorouracilcancerchitosandrug deliveryFe3O4fluorouracilgamma alumina

Identifiers

PMID36080138
PMCPMC9458215
OpenAlexW4292859984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.